Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval

Williams, Craig D.; Al-Jammali, Zain; Herink, Megan C.

doi:10.1007/s40265-022-01810-3

Cited by 7 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies suggest the analgesic effects of gabapentin and NB001/hNB001 may be through different mechanisms. A single application of gabapentin did not affect acute nociception and motor in naive mice (38, 39), but long-term application impaired inhibitory avoidance memory and produced adverse reactions (Table 1) (40,41). The effects of long-term use of NB001/hNB001 on the behaviors of adult mice had never been examined before, and we tested behavioral changes in adult mice after 30 consecutive days of oral administration of hNB001.…”

Section: Anxiety-like Behaviormentioning

confidence: 99%

Selective enhancement of fear extinction by inhibiting neuronal adenylyl cyclase 1 (AC1) in aged mice

Shi,

Chen,

et al. 2024

Preprint

View full text Add to dashboard Cite

Adenylyl cyclase 1 (AC1) is a selective subtype of ACs, which is selectively expressed in neurons. The activation of AC1 is activity-dependent, and AC1 plays an important role in cortical excitation that contributes to chronic pain and related emotional disorders. Previous studies have reported that human-used NB001 (hNB001, a selective AC1 inhibitor) produced analgesic effects in different animal models of chronic pain. However, the potential effects of hNB001 on learning and memory have been less investigated. In the present study, we found that hNB001 affected neither the induction nor the expression of trace fear, but selectively enhanced the relearning ability during the extinction in aged mice. By contrast, the same application of hNB001 did not affect recent, remote auditory fear memory, or remote fear extinction in either adult or aged mice. Furthermore, a single or consecutive 30-day oral administration of hNB001 did not affect acute nociceptive response, motor function, or anxiety-like behavior in either adult or aged mice. Our results are consistent with previous findings that inhibition of AC1 did not affect general sensory, emotional, and motor functions in adult mice, and provide strong evidence that inhibiting the activity of AC1 may be beneficial for certain forms of learning and memory in aged mice.

show abstract

Section: Anxiety-like Behaviormentioning

confidence: 99%

Selective enhancement of fear extinction by inhibiting neuronal adenylyl cyclase 1 (AC1) in aged mice

Shi,

Chen,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The second is the polypharmacy nature of these patients, which makes attributing specific outcomes or safety concerns to individual drugs challenging. However, in late 2019, the FDA issued a warning in light of the mounting evidence that gabapentinoids may cause respiratory suppression and are most dangerous when concomitantly used with other respiratory depressants, such as opioids [138,139].…”

Section: Gabapentinoidsmentioning

confidence: 99%

Drug Safety and Suicidality Risk of Chronic Pain Medications

Syed,

Jancic,

Fink

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Chronic pain is one of the main leading causes of disability in the world at present. A variety in the symptomatology, intensity and duration of this phenomenon has led to an ever-increasing demand of pharmacological treatment and relief. This demand for medication, ranging from well-known groups, such as antidepressants and benzodiazepines, to more novel drugs, was followed by a rise in safety concerns of such treatment options. The validity, frequency, and diversity of such concerns are discussed in this paper, as well as their possible effect on future prescription practices. A specific caution is provided towards the psychological safety and toll of these medications, regarding suicidality and suicidal ideation. Most significantly, this paper highlights the importance of pharmacovigilance and underscores the necessity of surveillance programs when considering chronic pain medication.

show abstract

“…In this context, 4% of the patients withdrew GBP due to adverse events [ 6 ]. In December 1993, the U.S. Food and Drug Administration (FDA) approved GBP as an adjuvant antiepileptic drug for focal seizures in adults [ 7 ]. Eventually, in 2002, GBP received U.S. FDA approval for treating post-herpetic neuralgia.…”

Section: Introductionmentioning

confidence: 99%

Gabapentin-Associated Movement Disorders: A Literature Review

Rissardo,

Medeiros Araujo de Matos,

Fornari Caprara

2023

Medicines

View full text Add to dashboard Cite

Background: Gabapentin (GBP)-induced movement disorders (MDs) are under-recognized adverse drug reactions. They are commonly not discussed with patients, and their sudden occurrence can lead to misdiagnosis. This literature review aims to evaluate the clinical–epidemiological profile, pathological mechanisms, and management of GBP-associated MD. Methods: Two reviewers identified and assessed relevant reports in six databases without language restriction between 1990 and 2023. Results: A total of 99 reports of 204 individuals who developed a MD associated with GBP were identified. The MDs encountered were 135 myoclonus, 22 dyskinesias, 7 dystonia, 3 akathisia, 3 stutterings, 1 myokymia, and 1 parkinsonism. The mean and median ages were 54.54 (SD: 17.79) and 57 years (age range: 10–89), respectively. Subjects were predominantly male (53.57%). The mean and median doses of GBP when the MD occurred were 1324.66 (SD: 1117.66) and 1033 mg/daily (GBP dose range: 100–9600), respectively. The mean time from GBP-onset to GBP-associated MD was 4.58 weeks (SD: 8.08). The mean recovery time after MD treatment was 4.17 days (SD: 4.87). The MD management involved GBP discontinuation. A total of 82.5% of the individuals had a full recovery in the follow-up period. Conclusions: Myoclonus (GRADE A) and dyskinesia (GRADE C) were the most common movement disorders associated with GBP.

show abstract

Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval

Cited by 7 publications

References 44 publications

Selective enhancement of fear extinction by inhibiting neuronal adenylyl cyclase 1 (AC1) in aged mice

Selective enhancement of fear extinction by inhibiting neuronal adenylyl cyclase 1 (AC1) in aged mice

Drug Safety and Suicidality Risk of Chronic Pain Medications

Gabapentin-Associated Movement Disorders: A Literature Review

Contact Info

Product

Resources

About